8 news items
Alnylam Issues 2023 Corporate Responsibility Report
ALNY
7 May 24
.
Expanded partnerships and strategies to support diversity and inclusion within clinical trials
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
ALNY
2 May 24
"Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
ALNY
30 Apr 24
candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
ALNY
30 Apr 24
that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
ALNY
7 Apr 24
"Alnylam P5x25" strategy to deliver transformative medicines in both rare and common
1ordkx wm0sllr5xccnwav0
ALNY
20 Mar 24
"Alnylam P5x25" strategy to deliver transformative medicines
jx3ifj933ayts2n1ivtd3i8ikc 09af5v1lq8c2lxk
ALNY
13 Mar 24
P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting
dprqb4tvoktul
ALNY
5 Mar 24
is executing on its "Alnylam P5x25" strategy to deliver
- Prev
- 1
- Next